Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Using a Speech-Generating Device to Support Communication in Rare Genetic Conditions

NCT: NCT07039084 · RECRUITING

NCT IDNCT07039084
StatusRECRUITING
Start Date2025-11-03
Completion2027-05

Brief Summary

Individuals with rare genetic conditions may experience a delay or loss of developmental skills. Many have limited verbal speech. The aim of this clinical trial is to examine how well a speech-generating device supports the communication skills of participants with a rare genetic condition. The speech-generating device is a communication program loaded onto an iPad. This is a crossover trial, meaning that each participant will receive both the treatment (device) and a control (usual care; no device) phase. The order in which each participant receives the device versus the usual care (no device) will depend on which group the participant is assigned to. The changes in communication in each phase will then be compared. During the trial, participants can expect to complete a series of assessments and attend a total of 2 x 1-hour therapy session per week for 6 weeks.

Frequently Asked Questions

What is Using a Speech-Generating Device to Support Communication in Rare Genetic Conditions?

Using a Speech-Generating Device to Support Communication in Rare Genetic Conditions is a clinical trial registered under NCT07039084. Current status: RECRUITING.

What is the status of NCT07039084?

The current status of NCT07039084 (Using a Speech-Generating Device to Support Communication in Rare Genetic Conditions) is: RECRUITING.

When did Using a Speech-Generating Device to Support Communication in Rare Genetic Conditions start?

Using a Speech-Generating Device to Support Communication in Rare Genetic Conditions started on 2025-11-03.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.